Global Contraceptive Market: Industry Analysis & Outlook (2018-2022)
Contraception, also referred to as birth control, is a method to control unwanted pregnancy. It has been used since ancient times; however, effective contraceptive methods have been introduced in 20th century only. Today, the market is filled with number of contraceptive options providing desirable results and efficacy. The global contraceptive market is experiencing a robust growth at a lucrative CAGR. Every year, a greater number of people undergoing contraceptive sterilization can be observed. Also, there is a high demand of male condoms due to their affordability, availability and higher efficiency to prevent pregnancy and exposure to sexually transmitted diseases (STDs).
Female contraception drug products are major boosters for the growth of the global contraceptive market. There is a continually growing population of females using hormonal contraception. Oral pills and IUDs are the widely used methods of contraception among females. The global female contraception drug market would continue to move forward with a healthy growth rate in future.
Regionally, the U.S. is the major market for contraceptives due to its increasing female population of childbearing age, higher concentration of key companies, higher awareness of contraceptives and STDs infections, and increasing consumption of female condoms. Also, the desirable size of a family in the U.S. is of two children which supports the consumption of contraceptives in the region. Europe also holds a notable share in the global contraceptive market. However, its share can drop to some extent in future due to decreasing female population of reproductive ages.
In terms of competition, the global contraceptive market is highly fragmented with a huge number of companies selling generic products. However, the global female contraceptive drug market is dominated by four companies that include Bayer AG, Allergan PLC, Merck & Co. and Teva Pharmaceuticals.
- 1. Overview
- 1.1 Contraceptive
- Table 1: Types of Contraceptive Methods
- 2. Global Contraceptive Market
- 2.1 Contraceptive Market Forecast by Value
- Table 2: Global Contraceptive Market Forecast by Value (2017-2022)
- 2.2 Contraceptive Market by Region
- Table 3: Global Contraceptive Market by Region (2017)
- 2.3 Female Contraceptive Drug Market Forecast by Value
- Table 4: Global Female Contraceptive Drug Market Forecast by Value (2017-2022)
- 2.4 Female Contraceptive Drug Market by Region
- Table 5: Global Female Contraceptive Drug Market by Region (2017)
- 2.5 Female Contraceptive User Volume Forecast
- Table 6: Global Female Contraceptive User Volume Forecast (2017-2022)
- 3. Regional Contraceptive Market
- 3.1 The U.S
- 3.1.1 The U.S. Contraceptive Market Forecast by Value
- Table 7: The U.S. Contraceptive Market Forecast by Value (2017-2022)
- 3.1.2 The U.S. Contraceptive Market by Type
- Table 8: The U.S. Contraceptive Market by Type (2017)
- 3.1.3 The U.S. Female Contraceptive Drug Market Forecast by Value
- Table 9: The U.S. Female Contraceptive Drug Market Forecast by Value (2017-2022)
- 3.1.4 The U.S. Contraceptive Script Volume Forecast
- Table 10: The U.S. Contraceptive Script Volume Forecast (2017-2022)
- 3.1.5 The U.S. Contraceptive Script Volume by Type
- Table 11: The U.S. Contraceptive Script Volume by Type (2017)
- 3.1.6 The U.S. Female Contraceptive User Volume Forecast
- Table 12: The U.S. Female Contraceptive User Volume Forecast (2017-2022)
- 3.2 Europe
- 3.2.1 Europe Contraceptive Market Forecast by Value
- Table 13: Europe Contraceptive Market Forecast by Value (2017-2022)
- 3.2.2 Europe Female Contraceptive Drug Market Forecast by Value
- Table 14: Europe Female Contraceptive Drug Market Forecast by Value (2017-2022)
- 3.2.3 Europe Contraceptive User Volume Forecast
- Table 15: Europe Contraceptive User Volume Forecast (2017-2022)
- 3.2.4 Europe Contraceptive User by Type
- Table 16: Europe Contraceptive User by Type (2017)
- 3.3 ROW
- 3.3.1 ROW Contraceptive Market Forecast by Value
- Table 17: ROW Contraceptive Market Forecast by Value (2017-2022)
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.1.1 Increasing Female Population of Reproductive Ages
- Table 18: The U.S. Female Population Forecast (Age 15-44 years) (2017-2022)
- 4.1.2 Growing Disposable Incomes
- Table 19: Global GNI per Capita (2013-2017)
- 4.1.3 Increasing Urban Population
- Table 20: Global Urban Population (2017)
- 4.2 Key Trends
- 4.2.1 Unmet Need for Family Planning
- Table 21: Number of Women with Unmet Need of Family Planning (in thousands) (2000-2030)
- 4.2.2 Pipeline Programs in Development
- Table 22: Late-Stage Contraceptive Programs
- 4.2.3 Increasing Use of Female Condoms
- 4.2.4 Increasing Trend of Non-Daily Dosing
- 4.3 Challenges
- 4.3.1 Decreasing Fertility Rates
- Table 23: Global Fertility Rate (2017)
- 4.3.2 Irregularities in Sex Education
- 4.3.3 Associated Risks
- 5. Competition
- 5.1 Global Market
- 5.1.1 Revenue Comparison of Key Players
- Table 24: Global Contraceptive Market- Revenue Comparison (2017)
- 5.1.2 Market Cap Comparison of Key Players
- Table 25: Market Cap Comparison of Key Players
- 5.1.3 Global Female Contraceptive Drug Market Share by Company
- Table 26: Global Female Contraceptive Drug Market Share by Company (2017)
- 6. Company Profiles
- 6.1 Bayer
- 6.1.1 Business Overview
- Table 27: Bayer Revenue by Segment (2017)
- 6.1.2 Financial Overview
- Table 28: Bayer Sales and Net Income (2013-2017)
- 6.1.3 Business Strategies
- Table 29: Bayer Research and Development Expenditure (2015-2017)
- 6.2 Merck & Co., Inc.
- 6.2.1 Business Overview
- Table 30: Merck & Co., Inc. Net Sales by Business Segments (2017)
- 6.2.2 Financial Overview
- Table 31: Merck & Co., Inc. Net Sales and Net Income (2013-2017)
- 6.2.3 Business Strategies
- Table 32: Merck & Co., Inc. Research and Development Expenditures (2015-2017)
- 6.3 Teva Pharmaceuticals
- 6.3.1 Business Overview
- Table 33: Teva Pharmaceuticals Revenue by Segments (2017)
- 6.3.2 Financial Overview
- Table 34: Teva Pharmaceuticals Revenue and Net Income (2013-2017)
- 6.3.3 Business Strategies
- Table 35: Teva Pharmaceuticals Research and Development Expenditures (2015-2017)
- 6.4 Allergan Plc
- 6.4.1 Business Overview
- Table 36: Allergan Plc Net Revenues by Business Segments (2017)
- 6.4.2 Financial Overview
- Table 37: Allergan Plc Net Revenues and Net Income (Loss) (2013-2017)
- 6.4.3 Business Strategies
- Table 38: Allergan Plc Research and Development Expenditures (2015-2017)